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was the only variable independently associated with leptin 
(B 0.485; p = 0.040).
Conclusions GH treatment modifies adipokine secretion 
and the perturbation of some adipokine levels could con-
tribute to the clinical and metabolic changes observed dur-
ing the follow-up.
Keywords Growth hormone · Children · Adipokines · 
Insulin sensitivity
Introduction
Growth hormone (GH) during childhood, in addition to 
promote linear growth, plays a key metabolic role and 
adipose tissue is known to be an important target for GH 
action [1]. Adipocytes secrete hormones known as adi-
pokines, many of which regulate metabolism and influence 
insulin sensitivity and secretion [2]. Untreated GH defi-
ciency (GHD) in children, as well as in adults, is associ-
ated with abnormalities in body composition, in addition to 
a cluster of cardiometabolic risk factors such as increased 
peripheral inflammatory markers and impairment in glu-
cose and lipid metabolism, and GH treatment seems to 
exert beneficial effects on most of these alterations [3–5].
Given the known effect of GH on adipose tissue and the 
role of adipokines in modulating metabolism and insulin 
homeostasis, many studies have evaluated the effect of GHD 
and GH treatment on the circulating levels of the most com-
mon adipokines, such as leptin and adiponectin. A nega-
tive impact on these adipokine levels has been reported in 
untreated GHD children, with a partial improvement during 
GH treatment, but with very discordant data across the stud-
ies. GHD seems to be associated with elevated leptin lev-
els which most likely reflect an increased fat mass in these 
Abstract 
Purpose The effect of growth hormone (GH) on adipose 
tissue and the role of adipokines in modulating metabolism 
are documented, but with discordant data. Our aim was to 
evaluate the impact of GH treatment on a series of selected 
adipokines known to have a metabolic role and poorly 
investigated in this setting.
Methods This is a prospective study. Thirty-one prepuber-
tal children (25 M, 6 F; aged 8.5 ± 1.6 years) with isolated 
GH deficiency treated with GH for at least 12 months and 
30 matched controls were evaluated. Auxological and met-
abolic parameters, insulin sensitivity indexes, leptin, solu-
ble leptin receptor, adiponectin, visfatin, resistin, omentin, 
adipocyte fatty acid-binding protein and retinol-binding 
protein-4 were evaluated before and after 12 months of 
treatment.
Results At baseline, no significant difference in metabolic 
parameters was found between GHD children and controls, 
except for higher LDL cholesterol (p = 0.004) in the first 
group. At multivariate analysis, LDL cholesterol was inde-
pendently associated with resistin (B 0.531; p = 0.002), 
while IGF-I was the only variable independently associated 
with visfatin (B 0.688; p < 0.001). After 12 months, a sig-
nificant increase in fasting insulin (p = 0.008), Homa-IR 
(p = 0.007) and visfatin (p < 0.001) was found, with a con-
comitant decrease in LDL cholesterol (p = 0.015), QUICKI 
(p = 0.001), ISI Matsuda (p = 0.006), leptin (p = 0.015) 
and omentin (p = 0.003)]. At multivariate analysis, BMI 
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patients [6] and a direct effect of GH on leptin production 
and metabolism is hypothesized [7] although this effect is 
not confirmed by all studies [8]. Conversely, adiponectin 
seems to be unaffected in untreated GHD, and GH treatment 
has been shown to have discordant effect on its levels [9, 10]. 
Similarly, the relationship between the modifications of adi-
pokine levels and the metabolic changes that occur in GHD 
children has not been unequivocally demonstrated [11, 12]. 
Given the discrepancies of the existing data about the role 
of the most investigated adipokines, our aim was to analyze 
in children affected by GHD how GH replacement modifies 
a series of new selected adipokines, known to have a meta-
bolic role and poorly investigated in this setting, and the rela-
tionship of these modifications with the metabolic changes.
Materials and methods
We prospectively studied 31 prepubertal children (25 M, 6 
F; mean age 8.5 ± 1.6 years; range 5.3–10.3) with isolated 
GHD consecutively admitted to the Section of Endocrinol-
ogy of the University of Palermo during the years 2013–
2014, treated with GH for at least 12 months and never 
investigated before in other clinical studies. Thirty prepu-
bertal healthy subjects, matched for sex (22 M, 8 F), age 
(mean age 8.9 ± 1.6 years; range 4.6–10.6) and BMI were 
recruited among children referred for assessment of short 
stature as a control group at baseline. All children, even the 
older ones, were in the first stage of sexual development to 
avoid any interference of the onset of puberty with insulin 
sensitivity and body composition and maintained the pre-
pubertal hormonal status during the observation period. For 
the same reasons, we excluded children affected by mul-
tiple pituitary hormone deficiency or receiving other hor-
monal replacement treatment, to exclusively evaluate the 
effects of GH. The diagnosis of GHD was established by 
the clinical, auxological and biochemical criteria of the GH 
Research Society [13].
As auxological data, we considered height and growth 
velocity 1 year before the diagnosis. Clinical and auxologi-
cal criteria included height more than 2 standard deviations 
(SDS) below the mean and a growth velocity over 1 year 
more than 1 SDS below the mean for age, or a decrease in 
height SDS of more than 0.5 over 1 year or, without severe 
short stature, a growth velocity more than 2 SDS below 
the mean over 1 year or, finally, height more than 1.5 SDS 
below the midparental height.
As a radiological criterion, we considered a bone age 
delay, estimated from an X-ray of the left wrist and hand 
and evaluated according to the methods of Greulich and 
Pyle, of at least 1 year with respect to the chronological age 
[14]. Biochemically, GHD was demonstrated by failure of 
GH to respond to an arginine and glucagon stimulation test, 
performed on two different days, with GH peaks below 
7 µg/l. Neuroimaging, with magnetic resonance imaging of 
the hypothalamic-pituitary region, in line with our protocol, 
was performed in children with signs pointing to multiple 
pituitary hormone deficiency or indicative of an intrac-
ranial lesion and in children with more severe GHD, like 
those with height more than 3 SDS below the mean, GH 
peak ≤ 3 μg/l or IGF-I levels below 2 SDS (No. 18 chil-
dren). Among them, three patients showed a pituitary hypo-
plasia and 2 a partial empty sella. The patients received GH 
once daily at bedtime with a pen injection system. During 
the entire follow-up, insulin-like growth factor (IGF)-I 
levels allowed us to determine the GH dose. Specifically, 
the target was IGF-I levels between 0.5 and 1.5 SDS. The 
initial daily dose of GH was 0.025 mg/Kg, increased to 
0.028 mg/Kg from month 6 to 12.
Study protocol
In all patients, after the diagnosis of GHD was made, the 
auxological and metabolic evaluation was performed at 
baseline and after 12 months of GH treatment, while in the 
control subjects these evaluations were performed only at 
baseline.
In addition to the measurement of body height, body 
mass index (BMI) and waist circumference (WC), in all 
children a blood sample was drawn after an overnight fast 
for the measurement of IGF-I, fasting glucose, fasting insu-
lin, Hemoglobin A1c (HbA1c) and lipid profile [total, high-
density lipoprotein (HDL) and low-density lipoprotein 
(LDL) cholesterol]. This sample also served as the baseline 
sample for an oral glucose tolerance test (OGTT). Blood 
samples were collected every 30 min for 2 h for glucose 
and insulin measurements.
Height, growth velocity, BMI and IGF-I were expressed 
as SDS due to the wide age range of patients.
As surrogate estimates of insulin sensitivity, we used the 
homeostasis model assessment estimate of insulin resist-
ance (Homa-IR) [15], the quantitative insulin sensitiv-
ity check index (QUICKI) [16] and the insulin sensitivity 
index (ISI), a composite index derived from the OGTT and 
validated by Matsuda and DeFronzo [17].
To evaluate the adipose function, in all children we 
measured the serum levels of leptin, soluble leptin receptor 
(sOB-R), adiponectin, visfatin, resistin, omentin, adipocyte 
fatty acid-binding protein (AFABP) and retinol-binding 
protein-4 (RBP4) after an overnight fast.
The institutional Ethics Committee of the University of 
Palermo approved this study. At the time of hospitalization, 
an informed consent for the scientific use of the data was 
obtained from both the participants and their parents.
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Hormone and biochemical assays
All biochemical data were collected after overnight fasting. 
Glycaemia and lipids were measured by standard methods 
(Modular P800, Roche, Milan). HbA1c levels were deter-
mined by HPLC (Bio-Rad Laboratories, Milan, Italy). 
Serum insulin was measured by ELISA (DRG Instru-
ments GmbH, Germany). The sensitivity of the method 
was 1 IU/ml. The normal insulin range (IU/ml) was 5–19. 
GH levels were measured by ELISA assay using commer-
cially available kits (hGH SENSITIVE ELISA Mediag-
nost E022, Germany). The sensitivity yields 0.0115 μg/l, 
with intra- and inter-assay coefficients of variation (CV) 
3.7–7.9 and 3.1–5.9 %, respectively. The 2nd International 
Standard NIBSC Code 98/574 was used as standard mate-
rial. Serum IGF-I was assayed in the same laboratory with 
ELISA assay (OCTEIA IGF-I kit, IDS Inc., Fountain Hills, 
AZ, USA). The sensitivity of the method was 1.9 µg/l. 
The inter- and intra-assay CV values were 7–7.1 and 2.3–
3.5 %, respectively, at IGF-I levels of 90.7–186 and 66.7–
120.9 µg/l, respectively. The normal ranges (males and 
females combined) of total IGF-I levels (µg/l) were the fol-
lowing: 12–108 (0–1 years); 13–100 (1–3 years); 26–280 
(3–6 years); 85–230 (6–9 years); 98–404 (9–12 years); 
142–525 (12–15 years); 146–415 (15–20 years). Values 
were expressed as SDS according to the normative data 
provided by the manufacturer. Human leptin (ng/ml), 
sOB-R (ng/ml), adiponectin (µg/ml), resistin (ng/ml), vis-
fatin (ng/ml), RBP4 (µg/ml), AFABP (ng/ml) and omen-
tin-1 (ng/ml) were assayed using an ELISA sandwich 
enzyme immuno-assay (BioVendor, Heidelberg, Germany).
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 
17 was used for data analysis. Baseline characteristics were 
presented as mean ± SDS or as median values ± inter-
quartile range (IR) for continuous variables, when appro-
priate (i.e. for the variables without normal distribution). 
Normality of distribution for quantitative variables was 
assessed with the Kolmogorov–Smirnov test. The differ-
ences between groups were evaluated with the t test when 
with normal distribution or with the Mann–Whitney test 
(nonparametric test) when without normal distribution. 
Pearson’s correlation was performed among continuous 
variables with normal distribution; correlations among con-
tinuous variables without normal distribution were deter-
mined using the Spearman’s test (nonparametric equivalent 
for Pearson test). To identify the independent variables 
which influence the adipokine levels, a linear regression 
model was performed. A p value <0.05 was considered sta-
tistically significant.
Results
Clinical and hormonal parameters
The clinical and hormonal features of control subjects and 
of GHD children at diagnosis and after 12 months of GH 
treatment are shown in Table 1.
No significant difference in height, BMI SDS and WC 
SDS between GHD children at baseline and control sub-
jects was found. As expected, GHD children at baseline 
showed significantly lower growth velocity (−2.7 ± 0.3 
vs. −1.5 ± 0.2 SDS; p < 0.001), IGF-I [−2.31 (−3.67 to 
−0.95) vs. 1.47 (−1.19–2.11) SDS; p < 0.001)] and GH 
peak after both arginine (4.3 ± 1.1 vs. 10.9 ± 2.6 µg/l; 
p < 0.004) and glucagon test (5.5 ± 1.1 vs. 16.2 ± 3.7 µg/l; 
p < 0.001) than controls.
In GHD children after 12 months, we observed a signifi-
cant increase in growth (height: −1.6 ± 0.6 vs. −2 ± 0.7 
SDS; p < 0.001; growth velocity: 1.3 ± 0.4 vs. −2.7 ± 0.3 
SDS; p < 0.001), with a concomitant significant increase in 
IGF-I [0.54 (0.07–1.15) vs. −2.31 (−3.67 to −0.95) SDS; 
p < 0.001)] and a decrease in BMI [− 0.80 (−2.64–1.25) 
vs. −0.39 (−2.26–1.81) SDS; p = 0.047)], without signifi-
cant change in WC SDS (Table 1).
Metabolic parameters
No significant difference was found in fasting glucose 
(4.6 ± 0.6 vs. 4.4 ± 0.2 mmol/l; p = 0.206), fasting insu-
lin [(2.4 (0.5–15.1) vs. 2.4 (0.8–6.6) IU/ml; p = 0.735)], 
HbA1c (5.2 ± 0.3 vs. 5.2 ± 0.3 %; p = 0.961) and insulin 
sensitivity indexes between GHD children at baseline and 
control subjects. GHD children showed higher LDL cho-
lesterol (2.4 ± 0.6 vs. 1.9 ± 0.1 mmol/l; p = 0.004) than 
controls, without any difference in triglycerides, total and 
HDL cholesterol (Table 1).
After 12 months of GH treatment, a significant increase 
in fasting insulin [6 (1.5–17.4) vs. 2.4 (0.5–15.1) IU/ml; 
p = 0.008)], and Homa-IR [1.3 (0.2–5.4) vs. 0.5 (0.1–4.2); 
p = 0.007)] was documented, with a concomitant decrease 
in LDL cholesterol (2.1 ± 0.6 vs. 2.4 ± 0.6 mmol/l; 
p = 0.015), QUICKI (0.36 ± 0.05 vs. 0.44 ± 0.08; 
p = 0.001) and ISI Matsuda [7.1 (2.6–22) vs. 17.2 (6.2–
37.7); p = 0.006)]. No significant change was observed in 
fasting glucose, HbA1c, triglycerides, total and HDL cho-
lesterol (Table 1).
Adipokine levels
Serum adipokine levels of control subjects, GHD children 
at baseline and after 12 months of GH treatment are shown 
in Table 2.
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At baseline GHD children showed significantly higher 
resistin [3.7 (1.4–7.8) vs. 3 (1–4.3) ng/ml; p = 0.007)] 
and lower visfatin [0.4 (0–10.1) vs. 2.9 (0.1–15.1) ng/ml; 
p = 0.011)] than controls, without significant difference in 
other adipokine levels.
At univariate analysis, resistin was found to be directly 
correlated with BMI (rho 0.318; p = 0.018) and LDL cho-
lesterol (rho 0.535; p < 0.001) and multivariate analysis 
confirmed the independent correlation between resistin and 
LDL cholesterol (B 0.531; p = 0.002) (Fig. 1).
Conversely, visfatin was found to have a significant 
inverse correlation with fasting glucose (rho −0.334; 
p = 0.019) and a direct correlation with IGF-I (rho 0.394; 
p = 0.021) and total cholesterol (rho 0.325; p = 0.027). 
IGF-I (B 0.688; p < 0.001) was the only variable inde-
pendently associated with visfatin at multivariate analysis 
(Fig. 1).
Adiponectin was directly correlated with ISI Matsuda 
(rho 0.341; p = 0.045) and QUICKI (rho 0.443; p = 0.005) 
and negatively with fasting insulin (rho −0.419; p = 0.008) 
and Homa-IR (rho −0.443; p = 0.005), but none of these 
Table 2  Serum adipokine 
levels of control subjects and 
GHD children at diagnosis 
(baseline) and after 12 months 
of GH treatment
Data are presented as mean ± standard deviation (SDS) or median ± interquartile range (IR), when appro-
priate
RBP4 retinol-binding protein-4, AFABP adipocyte fatty acid-binding protein
Control
group
(N. 30)
GHD
at baseline
(N. 31)
GHD
at 12 months
(N. 31)
p p*
Mean ± SD Mean ± SD Mean ± SD
Leptin (ng/ml) 1.5 (0.9–6.6) 1.5 (0.1–11.2) 1 (0.01–7.4) 0.980 0.015
Leptin receptor (sOB-R) (ng/ml) 26.2 (4.6–40) 21.4 (7.5–49) 20 (10.8–48.3) 0.721 0.189
Leptin/sOB-R ratio 0.05 (0.02–0.6) 0.05 (0–0.6) 0.05 (0–0.5) 0.316 0.891
Adiponectin (µg/ml) 14.35 ± 3.84 13.14 ± 4.72 13.37 ± 5.09 0.310 0.716
Resistin (ng/ml) 3 (1–4.3) 3.7 (1.4–7.8) 4.5 (2.4–20.1) 0.007 0.075
Visfatin (ng/ml) 2.9 (0.1–15.1) 0.4 (0–10.1) 3.4 (0–14.6) 0.011 <0.001
RBP4 (µg/ml) 18.17 ± 7.73 17.92 ± 6.23 17.10 ± 5.61 0.492 0.539
AFABP (ng/ml) 12.20 ± 4.40 13.77 ± 8.36 14.72 ± 8.57 0.939 0.483
Omentin (ng/ml) 334 (20.9–450) 304 (214–427) 283 (168–395) 0.221 0.003
Fig. 1  Independent variables 
influencing resistin, visfatin 
and leptin levels at multivariate 
analysis
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variables was independently correlated with adiponectin at 
multivariate analysis. No significant correlation with meta-
bolic parameters was found for the other adipokines evalu-
ated (data not shown).
After 12 months of treatment, we found a significant 
decrease in leptin [1 (0.01–7.4) vs. 1.5 (0.1–11.2) ng/
ml; p = 0.015)] and omentin levels [283 (168–395) vs. 
304 (214–427) ng/ml; p = 0.003)], with a concomitant 
increase in visfatin (3.4 (0–14.6) vs. 0.4 (0–10.1) ng/ml; 
p < 0.001). A trend in increase in resistin, although not 
statistically significant, was found [4.5 (2.4–20.1) vs. 3.7 
(1.4–7.8) ng/ml; p = 0.075)], while no significant change 
was found in sOB-R, adiponectin, resistin, AFABP and 
RBP4 (Table 2).
At univariate analysis, leptin levels at 12 months were 
found to be directly correlated with BMI (rho 0.683; 
p < 0.001), WC (rho 0.670; p < 0.001), fasting insulin (rho 
0.449; p = 0.013), Homa-IR (rho 0.591; p = 0.001) and 
inversely correlated with QUICKI (rho −0.432; p = 0.017). 
At multivariate analysis, BMI (B 0.485; p = 0.040) was the 
only variable independently associated with leptin (Fig. 1).
Visfatin at 12 months was found to be correlated with IGF-I 
(rho 0.572; p = 0.002), while omentin was negatively corre-
lated with fasting insulin (rho −0.484; p = 0.007) and Homa-
IR (rho −0.582 p = 0.001) and positively with ISI Matsuda 
(rho 0.648; p = 0.017). At multivariate analysis, none of the 
variables was independently associated with omentin. No sig-
nificant correlation with metabolic parameters was found for 
the other adipokines evaluated (data not shown).
Discussion
Overall, our results suggest that GH treatment exerts its 
metabolic effects in different ways. If on the one hand GH 
favorably affects adipose metabolism, as demonstrated by 
the improvement in lipid profile, reduction in leptin and 
increase in visfatin levels, on the other it acts by negatively 
altering the insulin sensitivity.
In our study, GHD children at diagnosis showed a worse 
metabolic panel, characterized by an unfavorable lipid 
profile and higher resistin levels. Several studies report an 
improvement in lipid profile after GH treatment [4], and 
our study also confirms this. Moreover, in our study, LDL 
cholesterol independently correlates with resistin levels, 
which are higher in GHD children than controls. Indeed, 
a possible mediator of the GH-modulated insulin sensi-
tivity may be resistin, which has been shown to be linked 
to obesity and insulin resistance [18]. Higher resistin lev-
els in untreated GHD children than controls have already 
been documented [19], while the effect of GH treatment is 
controversial. Our data are in agreement with some stud-
ies that have documented that GH treatment does not seem 
able to strongly modify resistin levels in GHD adults [10, 
20], although we found a trend to an increase in resistin 
levels after 12 months, though not statistically significant. 
Partially in line with our results, Nozue et al. [21] dem-
onstrated a rise in resistin after short-term GH therapy in 
GHD children, while López-Siguero et al. [12] showed a 
decline in resistin at 6 months of GH treatment and these 
data are in line with those of Meazza et al. [19] who 
showed a decrease in resistin levels. However, despite the 
lack of a statistically significant change, the trend to an 
increase in resistin in our patients during GH treatment is 
concomitant with a significant reduction in insulin sensi-
tivity, as demonstrated by the decline in QUICKI and ISI 
Matsuda, in line with previous studies. We already dem-
onstrated through euglycemic hyperinsulinemic clamp a 
decrease in insulin sensitivity in GHD children after GH 
treatment, even without evident changes in glucose toler-
ance [22] as well as a trend toward reduced insulin sensi-
tivity with a compensatory hyperinsulinemic response or 
increased insulin levels, but with normal glucose levels, 
after GH treatment have been demonstrated [23]. In our 
opinion, the lack of changes in resistin levels, despite the 
increase in insulin resistance indexes, can be explained by 
the other significant changes that occur during GH treat-
ment and that may impact the metabolic balance, such as 
the beneficial effects of GH on body composition and leptin 
levels. In our study, despite the lack of difference in leptin, 
sOB-R, BMI and WC between GHD children at baseline 
and controls, we found a significant decrease in leptin after 
GH treatment with an independent correlation with BMI, as 
demonstrated by other studies [24]. Notably, in this study, 
visfatin has proved to be the only adipokine to directly cor-
relate with IGF-I levels. Visfatin is thought to have insulin-
mimetic effects in various tissues [25] and it seems to be 
affected by weight loss, as demonstrated by Petelin et al. 
[26] in overweight subjects. Li et al. [27] showed higher 
visfatin levels in adults with GHD than controls, but to date 
data on visfatin during GH treatment are not available. We 
found lower visfatin in GHD children than controls at base-
line and a rise in its levels after GH treatment, concomi-
tantly with the increase in IGF-I. These data are partially in 
agreement with our previous data. Indeed, in acromegalic 
patients, we recently showed a correlation between vis-
fatin, insulin sensitivity and IGF-1 levels, concluding that 
visfatin in acromegaly could be considered a useful index 
of disease activity [28]. Therefore, the increase in visfatin 
in GHD children could represent a favorable metabolic 
effect of GH treatment, correlated with the IGF-I increase 
and independent of the deterioration in insulin sensitivity. 
Conversely, we found no difference in AFABP and RBP4 
levels, parameters known to be related with metabolic 
syndrome, cardiovascular risk factors and insulin resist-
ance [29, 30], between GHD children and controls, and 
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no significant change during GH treatment. These findings 
could be in line with some clinical studies which failed to 
show a relationship with metabolic parameters [31].
As regards adiponectin levels in GHD patients, the exist-
ing data are quite controversial. Adiponectin seems to be 
unaffected in untreated GHD [20], and GH treatment seems 
to have discordant effects on adiponectin, increasing it [12] 
or leaving it unchanged or slightly modifying it [10, 11]. 
We found a significant correlation between adiponectin and 
insulin sensitivity indexes at baseline, in line with other 
studies [32]. However, our data also confirm the unchanged 
adiponectin levels after GH treatment.
Finally, although no significant difference was found at 
baseline between GHD and controls, we surprisingly found 
a significant reduction in omentin levels after 12 months of 
treatment. It has been determined that omentin enhances 
insulin-stimulated glucose uptake in adipose tissue and 
many studies have shown that omentin is negatively corre-
lated with BMI and fat mass, insulin resistance and meta-
bolic syndrome [33, 34]. Our data are partially in agree-
ment with these findings. Indeed, a negative correlation 
between omentin and insulin resistance indexes was found 
after GH treatment, although it was not confirmed at multi-
variate analysis.
In conclusion, if this study is quite confirmatory for 
many of the parameters investigated, such as insulin sen-
sitivity and leptin levels, we showed for the first time the 
behavior of new selected adipokines, known to have a met-
abolic role and never investigated before in this setting, and 
their correlation with some metabolic and hormonal param-
eters. The action of GH could modify adipokine secretion, 
and the perturbation of some adipokine levels correlates 
with metabolic impairment. If resistin and omentin resulted 
differently correlated with some metabolic parameters, 
respectively, at baseline and after GH treatment, conversely 
visfatin proved to be strongly correlated with the hormo-
nal target in GHD subjects (as IGF-I), and leptin with body 
mass. In addition, during GH treatment, the favorable met-
abolic effects seem to be represented by a decrease in leptin 
and an increase in visfatin, while the negative effects seem 
to be represented by a decrease in omentin.
The main limitation of this study may be related to the 
small size of the population studied and to the short-term 
follow-up. In our opinion, these factors could be responsi-
ble for the lack of statistical significance in the evaluation 
of some adipokines. To better understand whether all the 
above-mentioned adipokines may represent a metabolic 
biomarker useful to identify the progression toward meta-
bolic abnormalities associated with GH treatment in GHD 
children, we believe that these data must be validated in 
additional larger prospective studies with longer follow-up, 
where patients are randomized to different GH doses.
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